Bayer Operating Income 2010-2023 | BAYRY

Bayer operating income from 2010 to 2023. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Bayer Annual Operating Income
(Millions of US $)
2023 $662
2022 $7,388
2021 $3,967
2020 $-18,470
2019 $4,692
2018 $4,622
2017 $6,672
2016 $7,793
2015 $6,940
2014 $7,319
2013 $6,554
2012 $5,093
2011 $4,582
2010 $2,677
2009 $2,906
Bayer Quarterly Operating Income
(Millions of US $)
2023-09-30 $-3,912
2023-06-30 $-1,042
2023-03-31 $3,191
2022-12-31 $1,274
2022-09-30 $1,208
2022-06-30 $180
2022-03-31 $4,727
2021-12-31 $2,373
2021-09-30 $625
2021-06-30 $-2,748
2021-03-31 $3,717
2020-12-31 $1,635
2020-09-30 $-10,987
2020-06-30 $-11,874
2020-03-31 $2,757
2019-12-31 $85
2019-09-30 $1,351
2019-06-30 $1,041
2019-03-31 $2,215
2018-12-31 $-4,971
2018-09-30 $5,143
2018-06-30 $1,611
2018-03-31 $2,839
2017-12-31 $203
2017-09-30 $1,631
2017-06-30 $2,366
2017-03-31 $2,472
2016-12-31 $798
2016-09-30 $2,003
2016-06-30 $2,415
2016-03-31 $2,576
2015-12-31 $916
2015-09-30 $1,741
2015-06-30 $2,028
2015-03-31 $2,255
2014-12-31 $600
2014-09-30 $1,826
2014-06-30 $2,021
2014-03-31 $2,873
2013-12-31 $916
2013-09-30 $1,617
2013-06-30 $1,681
2013-03-31 $2,339
2012-12-31 $934
2012-09-30 $1,049
2012-06-30 $964
2012-03-31 $2,146
2011-12-31 $378
2011-09-30 $1,427
2011-06-30 $1,507
2011-03-31 $1,220
2010-12-31 $-314
2010-09-30 $419
2010-06-30 $1,062
2010-03-31 $1,057
2009-12-31 $-82
2009-09-30 $1,199
2009-06-30 $829
2009-03-31 $1,097
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $713.355B 118.79
Novo Nordisk (NVO) Denmark $558.832B 46.04
Johnson & Johnson (JNJ) United States $348.864B 13.84
Merck (MRK) United States $317.566B 83.58
AbbVie (ABBV) United States $290.829B 14.78
AstraZeneca (AZN) United Kingdom $212.471B 18.83
Novartis AG (NVS) Switzerland $197.292B 13.67
Pfizer (PFE) United States $143.942B 13.89
Sanofi (SNY) $116.640B 10.50
Innoviva (INVA) United States $0.916B 6.46